Feb 27

Trian Fund Management, L.P.

Trian Fund Management, which holds 5% of Solventum, is pushing the healthcare company to divest its dental and software businesses to focus on its core medical-surgical unit.The activist investor argues Solventum's costs are too high and margins have stagnated since its spinoff from 3M, undermining expected post-separation growth.While Trian praised this week's $4.1 billion filtration unit sale to Thermo Fisher as progress, the firm wants management to implement further cost cuts before pursuing additional sales or spinoffs.